Targeted Therapy
Approved for: NSCLC
Biomarker: ROS1
Entrectinib (Rozlytrek) approved Targeted Therapy for non-small cell lung cancer (NSCLC) that is ROS1 positive. It is used in adults whose cancer has metastasized (spread to other parts of the body).
